[
  {
    "ts": null,
    "headline": "3 S&P 500 Stocks We Find Risky",
    "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
    "url": "https://finnhub.io/api/news?id=14dbd8cb3b927457913f169f2301f529d0fff54bc27a6afc10ccbb63b9b3e7ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718224,
      "headline": "3 S&P 500 Stocks We Find Risky",
      "id": 137127517,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
      "url": "https://finnhub.io/api/news?id=14dbd8cb3b927457913f169f2301f529d0fff54bc27a6afc10ccbb63b9b3e7ab"
    }
  },
  {
    "ts": null,
    "headline": "SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025",
    "summary": "SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Iza-bren is jointly developed by SystImmune and Br",
    "url": "https://finnhub.io/api/news?id=961a9b5c8e3fa1872c2c069fd776fafd81d559b8e2dc1a530b2cbaf05c8042bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760709600,
      "headline": "SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025",
      "id": 137125903,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Iza-bren is jointly developed by SystImmune and Br",
      "url": "https://finnhub.io/api/news?id=961a9b5c8e3fa1872c2c069fd776fafd81d559b8e2dc1a530b2cbaf05c8042bf"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India",
    "summary": "New initiative aims to build capacity in high-prevalence areas to increase screening and prevention of hemoglobinopathies NORTHAMPTON, MA / ACCESS Newswire / October 17, 2025 /PATH has launched a groundbreaking initiative to address the rising burden ...",
    "url": "https://finnhub.io/api/news?id=20004aade1f422e368e6a9127815b37fa9f277449ed2f2237658b1d0994e3a8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760698800,
      "headline": "Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India",
      "id": 137125905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "New initiative aims to build capacity in high-prevalence areas to increase screening and prevention of hemoglobinopathies NORTHAMPTON, MA / ACCESS Newswire / October 17, 2025 /PATH has launched a groundbreaking initiative to address the rising burden ...",
      "url": "https://finnhub.io/api/news?id=20004aade1f422e368e6a9127815b37fa9f277449ed2f2237658b1d0994e3a8e"
    }
  },
  {
    "ts": null,
    "headline": "In the Wake of Bristol Myers' $1.5B Business Acquisition, LegalMatch.com Emphasizes the Need for Expert Legal Guidance in Mergers",
    "summary": "LegalMatch Highlight Critical Legal Considerations in Major Business Mergers and Acquisitions RENO, NEVADA / ACCESS Newswire / October 17, 2025 / Following the recent $1.5 billion acquisition of privately held Orbital Therapeutics by Bristol Myers ...",
    "url": "https://finnhub.io/api/news?id=1d345f4296bb897c8ac7b0adbf5bd2d0d1d5d691b223f341244d78333b5e8fbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760698800,
      "headline": "In the Wake of Bristol Myers' $1.5B Business Acquisition, LegalMatch.com Emphasizes the Need for Expert Legal Guidance in Mergers",
      "id": 137125904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "LegalMatch Highlight Critical Legal Considerations in Major Business Mergers and Acquisitions RENO, NEVADA / ACCESS Newswire / October 17, 2025 / Following the recent $1.5 billion acquisition of privately held Orbital Therapeutics by Bristol Myers ...",
      "url": "https://finnhub.io/api/news?id=1d345f4296bb897c8ac7b0adbf5bd2d0d1d5d691b223f341244d78333b5e8fbb"
    }
  },
  {
    "ts": null,
    "headline": "Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More",
    "summary": "Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More",
    "url": "https://finnhub.io/api/news?id=e50a71b35a4fa3b673b51ef5aa39002123bc9802237cb49df26d3eaa80a85779",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760696235,
      "headline": "Undercovered Dozen: NANO Nuclear Energy, Zeta Global, Blue Owl And More",
      "id": 137125274,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e50a71b35a4fa3b673b51ef5aa39002123bc9802237cb49df26d3eaa80a85779"
    }
  }
]